How Isomorphic Labs Makes Money | Business Model

How it started (problem, solution, target audience)

Let’s be honest, traditional drug discovery is a slow, painful grind. Researchers burn years just staring at proteins, trying to find a “binding pocket”-the exact entry point a drug needs to neutralize a diseased cell. It is brutal. And most of the time, the manual prep work drains your capital before the real science even begins.

So, in 2021, Alphabet spun Isomorphic Labs out of Google DeepMind to attack this from first principles. Demis Hassabis-who won half the 2024 Nobel Prize in chemistry for AlphaFold 2-is running the show. The reality is, they built the Isomorphic Labs Drug Design Engine, or IsoDDE, specifically to automate this manual nightmare. It targets major pharma companies looking to cure devastating diseases.

Competitive advantage

You want an edge? Here is the kicker. IsoDDE doesn’t just match baseline models. When they ran it through the “Runs N’ Poses” benchmark, it more than doubled AlphaFold 3’s score on the absolute hardest tasks. It is fast. It is precise.

But it also requires significantly less data to start hunting for those pockets, which saves months of prep work. And once it finds the pocket, it accurately predicts a compound’s “binding affinity”-How Johnson & Johnson Makes Money | The Business Model Behind Healthcare’s Most Diversified Giantwhether the drug will actually stick to the protein. Plus, they are using the next generation of AlphaFold, which expands beyond proteins to small molecules and nucleic acids. Having Alphabet’s massive computing power in your corner doesn’t hurt either.

Marketing Technique of Isomorphic Labs

How do you sell a fundamentally new approach? You don’t run traditional ads. You secure massive, high-profile collaborations. Isomorphic kicked off 2024 by signing multi-target research deals focused on small molecules with giants like Eli Lilly and Novartis. That is the ultimate validation.

They also leverage strategic public relations. They broadcast major milestones, like their $600 million Series B led by Thrive Capital and the appointment of Dr. Ben Wolf as Chief Medical Officer. That signals to the market they are serious about building a US presence and moving toward actual clinical trials.

How Isomorphic Labs makes money

Let’s talk revenue. You need cash flow to survive. Isomorphic operates on a B2B partnership model. First, they get upfront cash. Eli Lilly handed them $45 million just to start, and Novartis chipped in another $37.5 million.

But the real money is in the milestones. They are eligible for up to $1.7 billion in performance milestones from Lilly and $1.2 billion from Novartis. If the drugs actually make it to market, Isomorphic gets tiered royalties on net sales, ranging up to the low double digits. It is a massive upside.

Market share of Isomorphic Labs

The reality is, exact market share percentages aren’t disclosed in these early stages. But we know exactly who is in the arena. Tracxn ranks Isomorphic 12th out of 167 active competitors.

Competitor Name	Total Funding	Key Investors	Tracxn Score
Schrodinger	$162M	Gates, WuXi AppTec & others	74/100
Recursion Pharmaceuticals	$452M	Baillie Gifford, Felicis & others	72/100
XtalPi	$785M	Orbimed, SoftBank & others	67/100
Isomorphic Labs	$600M	Thrive Capital, Alphabet, GV	62/100

Business Model canvas

• Key Partners: Alphabet, Google DeepMind, Thrive Capital, Andreessen Horowitz, Eli Lilly, and Novartis.
• Key Activities: Developing IsoDDE, analyzing small molecules, predicting protein structures, and gearing up for 2026 clinical trials.
• Key Resources: Next-gen AlphaFold, massive computing infrastructure, and elite AI and biology talent.
• Value Proposition: Automating the manual research grind, drastically improving binding affinity predictions, and saving years of prep work.
• Customer Segments: Major pharmaceutical companies.
• Revenue Streams: Upfront cash, billion-dollar performance milestones, and royalties.

Conclusion: Is it a viable business

So, is this a viable business? Absolutely. They just raised a $600 million Series B at a $3.5 billion valuation, and reports say they are already negotiating a new round worth over $2 billion. They have nearly $3 billion in potential deal value sitting on the table from the Novartis and Eli Lilly partnerships alone.

It’s lonely. It’s hard. But it works. With Alphabet’s infrastructure backing them and a clear revenue model, they have the runway to push this forward. They are gunning for their first human drug trials in 2026. If they pull it off, it changes everything.